The effects of bendroflumethiazide added to nifedipine in patients with hypertension.
It has been suggested that a diuretic added to a calcium antagonist may not reduce blood pressure further in patients with hypertension. Bendroflumethiazide 5 mg was given to 17 patients with essential hypertension who had persistent mild to moderate hypertension despite treatment with nifedipine slow-release tablets 20 mg bid. One group received bendroflumethiazide before (N = 8) and the other after placebo (N = 9) in a double-blind, randomized cross-over trial. Supine blood pressure following active bendroflumethiazide administration was significantly reduced in both groups compared with trial entry (166/105 to 150/96 mm Hg, P less than .01; 170/108 to 156/98 mm Hg, P less than .01). A reduction in serum potassium level and a rise in serum uric acid concentration were seen with combined treatment. We cannot substantiate theoretic arguments for the ineffectiveness of a bendroflumethiazide-nifedipine combination on blood pressure.
Zezulka
A V
AV
University Department of Medicine, Dudley Road Hospital, Birmingham, England, United Kingdom.
Gill
J S
JS
Beevers
D G
DG
D000328:Adult; D001539:Bendroflumethiazide / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008875:Middle Aged; D009543:Nifedipine / Q000009:adverse effects / Q000627:therapeutic use*; D011188:Potassium / Q000097:blood; D011674:Pulse / Q000187:drug effects; D011897:Random Allocation; D014527:Uric Acid / Q000097:blood
D001786:Blood Glucose; D003692:Delayed-Action Preparations; D014527:Uric Acid; D001539:Bendroflumethiazide; D009543:Nifedipine; D011188:Potassium